Velcade
Named-patient access overview. Velcade is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Velcade (bortezomib) is a first-in-class reversible 26S proteasome inhibitor developed by Millennium Pharmaceuticals, now part of Takeda Oncology. The US Food and Drug Administration first approved Velcade in May 2003 for relapsed and refractory multiple myeloma, with a full approval for frontline multiple myeloma granted in June 2008 and an additional approval for mantle cell lymphoma in patients who have received at least one prior therapy. Velcade is administered as a subcutaneous or intravenous bolus injection at 1.3 mg/m2 on a twice-weekly or weekly schedule, typically given in a hospital outpatient infusion suite or specialty oncology clinic. Reserve Meds coordinates physician-led cross-border sourcing for international patients.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Velcade
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Velcade is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Velcade in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Velcade
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.